Sarcopenia (SARA) : discussions engaged with FDA for the preparation of a Phase 2-3 program in sarcopenia, with the objective of having a First Patient In by end of H2 2022
COVID-19 (COVA): 237 patients enrolled - early termination of recruitment due to global drop of COVID-19 hospitalizations - results for the phase 2-3 study will be reported in Q3 2022
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.